Project Grant R01HL174570
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$1.8M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
This federal Project Grant award, valued at $2,241,717.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at defining the spatiotemporal profile and cellular heterogeneity of marginal zone B and B1 cell-specific protein (MZB1)+ B and plasma cell populations in the development of chronic rejection after lung transplantation. The overarching goal is to interrogate the mechanistic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $452,181 to develop and test an 8-week exercise-based frailty intervention called XFIT for lung transplant candidates. The goal is to improve physical function and reduce frailty in this population at high risk for disability and mortality. The award includes sub-grants to Columbia University ($352,181) and the University of Pennsylvania ($100,000) to serve as study...
This Project Grant award of $126,099.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate molecular phenotypes of frailty in lung transplantation. The principal investigator, an Associate Professor and lung transplant pulmonologist, will leverage existing research programs and collaborations to examine the heterogeneous pathobiology of pre- and...
This $2,803,961 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research effort to investigate the mechanisms underlying primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The research team at Northwestern University will conduct four interrelated projects to better understand the role of lung-restricted alloantibodies,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $799,354 to Northwestern University to conduct research on the role of necroptosis in primary graft dysfunction following lung transplantation. The project aims to comprehensively understand and target the necroptotic pathways in both the donor and recipient lungs to reduce the high incidence of primary graft dysfunction, which...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $1,564,220.00 to The Trustees of the University of Pennsylvania to develop an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system. The goal is to obtain structural, functional, and metabolic biomarkers that can be used to non-invasively assess donor lung health and optimize EVLP parameters for reconditioning lungs prior...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate the molecular mechanisms connecting primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) after lung transplantation. The $798,958 award to Northwestern University aims to determine whether activation of the integrated stress response (ISR) in the airway and alveolar...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $742,810 to the University of Virginia to develop hyperpolarized gas MRI (HGMRI) signatures for detecting and monitoring acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, treatment response, and single-cell RNA-sequencing data to enhance early...
This $804,438 federal Project Grant award from the National Heart, Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a prospective, multi-center study to develop a non-invasive blood test using circulating microRNAs to monitor the net immune state of adult heart transplant patients. The goal is to identify microRNA biomarkers that can predict and monitor the risks of over- and under-immunosuppression to help clinicians personalize post-transplant medication...
This Project Grant award of $134,123.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to enhance the ability to identify and treat pediatric hematopoietic cell transplant (HCT) patients with or at-risk for pulmonary fibrosis (PF). The primary goals are to identify bronchoalveolar lavage fluid (BAL) and blood-based transcriptomic and proteomic signatures that differentiate HCT patients with and without PF, and to...